Finance

Lists
QURE:NASDAQ
Uniqure NV
20,97 US$
-1,46%
(-0,31) 1D
20,63 US$
-1,62% (-0,34)
Pre-market
Closed: 14 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QURE...
Open
21,00 US$
High
21,75 US$
Low
20,33 US$
Mkt. cap
1,45 მლრდ.
Avg. vol.
2,83 მლნ.
Volume
2,28 ათ.
52-wk high
71,50 US$
52-wk low
8,73 US$
EPS
-4,05 US$
Beta
1,06
Shares outstanding
69,37 მლნ.
No. of employees
221
Open
21,00 US$
High
21,75 US$
Low
20,33 US$
Mkt. cap
1,45 მლრდ.
Avg. vol.
2,83 მლნ.
Volume
2,28 ათ.
52-wk high
71,50 US$
52-wk low
8,73 US$
EPS
-4,05 US$
Beta
1,06
Shares outstanding
69,37 მლნ.
No. of employees
221
News stories
From web sources and news partners
Profile
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies. Wikipedia
About Uniqure NV
CEOMatt Kapusta
Employees221
Founded1998
Headquarters-
Sector-
Analyst ratings
Based on 10 analysts giving stock ratings to QURE in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for QURE in the last 3 months.
Highest
Current 20,97 US$
80,00 US$ (+281,50%)
Average
53,57 US$ (+155,46%)
Lowest
28,00 US$ (+33,52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joon Lee
UBS
Buy
Initiated
48,00 US$
+128,9%
10/14/2026
Unknown Analyst
UBS
Buy
Initiated
48,00 US$
+128,9%
10/14/2026
Eliana Merle
Barclays
Hold
Downgraded
28,00 US$
+33,5%
10/06/2026
Luca Issi
RBC Capital
Buy
Reiterated
48,00 US$
+128,9%
10/02/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
31,00 US$
+47,8%
09/30/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
75,00 US$
+257,7%
09/29/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
80,00 US$
+281,5%
09/30/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/29/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
-
-
09/29/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/02/2026
Sami Corwin
William Blair
Buy
Initiated
73,00 US$
+248,1%
09/02/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
68,00 US$
+224,3%
07/29/2026
Rudy Li
Wolfe Research
Buy
Upgraded
65,00 US$
+210%
07/29/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
70,00 US$
+233,8%
06/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Upgraded
-
-
06/17/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
37,00 US$
+76,4%
05/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
95,00 US$
+353%
05/05/2026
Last report
29 ივლ. 2026
Fiscal period
Q2 2026
-1,07 € / -0,71 €
-51,25%miss
Revenue / Est. (EUR)
5,13 მლნ. / 4,32 მლნ.
+18,66%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
3,70 მლნ.
5,57 მლნ.
3,56 მლნ.
5,84 მლნ.
Cost of goods sold
32,25 მლნ.
40,18 მლნ.
30,73 მლნ.
30,66 მლნ.
Cost of revenue
32,25 მლნ.
40,18 მლნ.
30,73 მლნ.
30,66 მლნ.
Research and development expenses
695,00 ათ.
-5,92 მლნ.
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19,44 მლნ.
21,61 მლნ.
20,07 მლნ.
19,77 მლნ.
Operating expense
20,67 მლნ.
15,55 მლნ.
19,89 მლნ.
26,13 მლნ.
Total operating expenses
52,91 მლნ.
55,73 მლნ.
50,62 მლნ.
56,79 მლნ.
Operating income
-49,21 მლნ.
-50,16 მლნ.
-47,06 მლნ.
-50,95 მლნ.
Other non operating income
-7,22 მლნ.
18,13 მლნ.
3,77 მლნ.
-15,97 მლნ.
EBT including unusual items
-71,90 მლნ.
-41,00 მლნ.
-53,05 მლნ.
-79,22 მლნ.
EBT excluding unusual items
-70,08 მლნ.
-40,05 მლნ.
-54,38 მლნ.
-77,96 მლნ.
Income tax expense
8,63 მლნ.
-3,92 მლნ.
488,00 ათ.
1,84 მლნ.
Effective tax rate
-12,00%
9,55%
-0,92%
-2,32%
Other operating expenses
534,00 ათ.
-143,00 ათ.
-181,00 ათ.
6,36 მლნ.
Net income
-80,53 მლნ.
-37,09 მლნ.
-53,54 მლნ.
-81,06 მლნ.
Net profit margin
-2 175,87%
-666,06%
-1 502,95%
-1 387,76%
Earnings per share
-
-
-
-
Interest and investment income
3,50 მლნ.
5,81 მლნ.
5,23 მლნ.
5,05 მლნ.
Interest expense
-16,72 მლნ.
-14,57 მლნ.
-14,03 მლნ.
-14,37 მლნ.
Net interest expenses
-13,22 მლნ.
-8,76 მლნ.
-8,80 მლნ.
-9,32 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-45,58 მლნ.
-47,19 მლნ.
-44,10 მლნ.
-46,04 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები